These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 22110208

  • 1. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Cho YB, Chung HJ, Lee WY, Choi SH, Kim HC, Yun SH, Chun HK.
    Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
    [Abstract] [Full Text] [Related]

  • 2. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Azuma M, Mori R, Omori A, Lenz HJ, Danenberg KD, Danenberg PV.
    Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [Abstract] [Full Text] [Related]

  • 4. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
    Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ.
    J Clin Oncol; 2001 Dec 01; 19(23):4298-304. PubMed ID: 11731512
    [Abstract] [Full Text] [Related]

  • 5. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F.
    Clin Cancer Res; 2005 Sep 01; 11(17):6212-7. PubMed ID: 16144923
    [Abstract] [Full Text] [Related]

  • 6. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW.
    Cancer Chemother Pharmacol; 2010 Aug 01; 66(3):493-500. PubMed ID: 19960344
    [Abstract] [Full Text] [Related]

  • 7. ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells.
    Torii Y, Kato R, Minami Y, Hasegawa K, Fujii T, Udagawa Y.
    Anticancer Res; 2014 Jan 01; 34(1):107-15. PubMed ID: 24403450
    [Abstract] [Full Text] [Related]

  • 8. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
    Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE, Danenberg PV, Harpole DH.
    Clin Cancer Res; 2005 Mar 15; 11(6):2215-21. PubMed ID: 15788669
    [Abstract] [Full Text] [Related]

  • 9. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
    Li S, Zhu L, Yao L, Xia L, Pan L.
    BMC Gastroenterol; 2014 Aug 29; 14():154. PubMed ID: 25175730
    [Abstract] [Full Text] [Related]

  • 10. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, Schneider PM, Danenberg PV.
    J Am Coll Surg; 2005 Mar 29; 200(3):336-44. PubMed ID: 15737843
    [Abstract] [Full Text] [Related]

  • 11. [Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion of colorectal cancer].
    Ishibashi K, Okada N, Tajima Y, Ishiguro T, Kuwabara K, Ohsawa T, Kumamoto K, Tsuji Y, Haga N, Iwama T, Ishida H, Onouchi T, Yakabi K.
    Gan To Kagaku Ryoho; 2011 Nov 29; 38(12):2220-3. PubMed ID: 22202336
    [Abstract] [Full Text] [Related]

  • 12. Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer.
    Noda E, Maeda K, Inoue T, Fukunaga S, Nagahara H, Shibutani M, Amano R, Nakata B, Tanaka H, Muguruma K, Yamada N, Yashiro M, Ohira M, Ishikawa T, Hirakawa K.
    Hepatogastroenterology; 2012 Nov 29; 59(113):130-3. PubMed ID: 21940361
    [Abstract] [Full Text] [Related]

  • 13. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
    Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y, Kurumi Y, Tani T.
    Cancer Chemother Pharmacol; 2008 Apr 29; 61(4):587-94. PubMed ID: 17520254
    [Abstract] [Full Text] [Related]

  • 14. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T, Ferraz JM, Zinzindohoué F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P.
    Clin Cancer Res; 2004 Sep 01; 10(17):5880-8. PubMed ID: 15355920
    [Abstract] [Full Text] [Related]

  • 15. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H.
    Dis Colon Rectum; 2011 Aug 01; 54(8):1026-35. PubMed ID: 21730794
    [Abstract] [Full Text] [Related]

  • 16. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M.
    J Clin Oncol; 2007 Apr 01; 25(10):1247-54. PubMed ID: 17401013
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
    Seetharam RN, Sood A, Basu-Mallick A, Augenlicht LH, Mariadason JM, Goel S.
    Anticancer Res; 2010 Jul 01; 30(7):2531-8. PubMed ID: 20682979
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ.
    Br J Cancer; 2004 Jul 19; 91(2):344-54. PubMed ID: 15213713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.